TITLE:
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

CONDITION:
Multiple Sclerosis, Relapsing-Remitting

INTERVENTION:
Natalizumab

SUMMARY:

      The purpose of this study is to determine if natalizumab in combination with Glatiramer
      Acetate (GA) is safe and effective in delaying progression of individuals diagnosed with
      relapsing-remitting Multiple Sclerosis (MS).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 55 Years
Criteria:

        Inclusion Criteria:

          -  Diagnosis of MS as defined by McDonald et al., criteria # 1-4

          -  Between the ages of 18 and 55, inclusive

          -  Baseline EDSS score between 0.0 and 5.0, inclusive

          -  Have been treated with GA for at least the 12 months prior to randomization

        Exclusion Criteria:

          -  Primary progressive, secondary progressive or progressive relapsing MS

          -  MS relapse has occurred within the 50 days prior to randomization

          -  A clinically significant infectious illness

          -  History of, or abnormal lab result indicative of significant disease that would
             preclude the administration of a recombinant humanized antibody immunomodulating
             agent or GA for 20 weeks.
      
